

COVID ROOC

More Information Bank

INTERNATIONAL FOCUS

Note: Not all sources are peer-reviewed whereas some are reviews and interesting blogs. They are not intended in themselves to guide patient management decisions.

[Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors \(June, 2022\)](#)

[COVID-19 & Other Global Health Issues Virtual \(June, 2022\)](#)

[Skin manifestations of COVID-19: A global perspective \(April, 2022\)](#)

[This month in JAAD International: March 2022: Photography, skin cancer, and the limits of teledermatologic during the COVID-19 pandemic \(March, 2022\)](#)

[Challenges for dermatologists during the COVID-19 pandemic: A qualitative study \(March, 2022\)](#)

[Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problem \(August, 2022\)](#)

[Teledermatology for suspected skin cancer in New Zealand during the COVID-19 pandemic required in-person follow-up in 28% of cases \(March, 2022\)](#)

[WHO recommends two new drugs to treat COVID-19. \(January, 2022\)](#)

[COVID-19 Weekly Epidemiological Update. \(October, 2021\)](#)

[WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients. \(August, 2021\)](#)

[Early signs COVID-19 vaccines may not stop Delta transmission, England says. August, 2021\)](#)

[Australia's COVID Crisis: Victoria Enters 6th Lockdown As New South Wales Cases Hit New Record. \(August, 2021\)](#)

[Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. \(April, 2021\)](#)

[Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. \(April, 2021\)](#)

[Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. \(March, 2021\)](#)

[High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. \(February, 2021\)](#)

[Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences. \(June, 2020\)](#)

[Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. \(April, 2020\)](#)

